RVAC Medicines Pte. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
RVAC Medicines Pte. Ltd. - overview
Established
2021
Location
-, -, Singapore
Primary Industry
Biotechnology
About
Based in Singapore, and founded in 2021 by its CEO Sean Fu, and CSO Jason Zhang, RVAC Medicines Pte. Ltd. operates as a messenger (mRNA) ribonucleic acid platform company. In April 2022, RVAC Medicines Pte.
Ltd. raised USD 140 million in series B funding led by new investor CBC Group, with participation from other new investors EDBI, GS Holdings, and Pavilion Capital. RVAC Medicines provides GMP manufacturing capabilities; MSAT infrastructure for process scale-up and tech transfer; develops single and multi-mRNA/DNA products, etc. The company plans to use the April 2022 funding to accelerate the development of a multivalent COVID vaccine.
Current Investors
SG Growth Capital, Pavilion Capital, CBC Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.rvacmed.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.